Description

Early Detection of Alzheimer’s Disease | Blood-Based Biomarker Test | Non-Invasive Cognitive Screening

The Lumipulse G1200 pTau 217 / Beta-Amyloid 1-42 Plasma Ratio Test is a cutting-edge blood test designed to help detect early signs of Alzheimer’s disease and assess the risk of cognitive decline.

This test uses advanced immunoassay technology to measure plasma levels of phosphorylated tau 217 (p-Tau 217) and beta-amyloid 1-42 (Aβ1-42)—two of the most important biomarkers linked to Alzheimer’s pathology. It provides a convenient and minimally invasive alternative to PET scans or spinal taps.

Purpose of the Test

  • Screen for early-stage Alzheimer’s disease risk
  • Evaluate biomarker changes before cognitive symptoms appear
  • Support neurological assessments and diagnostic decisions
  • Aid in clinical trials or ongoing monitoring of cognitive decline
  • Offer a less invasive option than cerebrospinal fluid (CSF) testing

Who Should Consider This Test?

  • Individuals with mild memory loss or cognitive symptoms
  • People with a family history of Alzheimer’s or dementia
  • Adults aged 50 and older interested in early brain health screening
  • Healthcare providers seeking biomarker confirmation for diagnosis
  • Patients enrolled in neurological research or treatment programs

What the Test Measures

  • Phosphorylated tau 217 (p-Tau 217): Elevated levels are associated with neurofibrillary tangle formation—a hallmark of Alzheimer’s disease.
  • Beta-Amyloid 1-42 (Aβ1-42): Decreased levels in the blood reflect amyloid plaque buildup in the brain.
  • pTau 217 / Aβ1-42 Ratio: A powerful combined biomarker used to identify the presence of Alzheimer-type changes with high accuracy.

A higher ratio is linked to greater likelihood of Alzheimer’s-related brain changes. Results should be interpreted alongside clinical findings and neurological evaluations.

Fasting Required?

No fasting required.